|
|
Article: Entropin, Inc. Starts Phase III Clinical Trials of its Esterom Solution For the Treatment of Impaired Shoulder Function.
- Article from:
- PR Newswire
- Article date:
- December 9, 1999
CopyrightCOPYRIGHT 1999 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
INDIO, Calif., Dec. 9 /PRNewswire/ -- Entropin, Inc. (OTC Bulletin Board: ETOP) today announced that it has started Phase III clinical trials of its topically applied Esterom(R) solution for the treatment of acute impaired shoulder function.
"This is a major milestone for our Company," stated Higgins D. Bailey, Ed.D., Chairman of Entropin. "Our objective was to commence these pivotal trials no later than the fourth quarter of 1999 and we have met that objective."
Approximately 600 patients suffering from a dysfunctional shoulder will be selected for the Phase III clinical trials. Phase III will be conducted in two segments, Phase III A and Phase III B. ...